Case Series: Deep Brain Stimulation for Facial Pain.


Journal

Operative neurosurgery (Hagerstown, Md.)
ISSN: 2332-4260
Titre abrégé: Oper Neurosurg (Hagerstown)
Pays: United States
ID NLM: 101635417

Informations de publication

Date de publication:
15 10 2020
Historique:
received: 24 01 2020
accepted: 13 04 2020
pubmed: 17 6 2020
medline: 22 6 2021
entrez: 17 6 2020
Statut: ppublish

Résumé

Deep brain stimulation (DBS) has been used for chronic pain for decades, but its use is limited due to a lack of reliable data about its efficacy for specific indications. To report on 9 patients who underwent DBS for facial pain, with a focus on differences in outcomes between distinct etiologies. We retrospectively reviewed 9 patients with facial pain who were treated with DBS of the ventral posteromedial nucleus of the thalamus and periventricular gray. We report on characteristics including facial pain etiology, complications, changes in pain scores using the visual analog scale (VAS), and willingness to undergo DBS again. Nine patients underwent DBS for either poststroke, post-traumatic, postherpetic, or atypical facial pain. Eight patients (89%) were permanently implanted. Seven patients had sufficient follow-up (mean 40.3 mo). Of these 7 patients, average VAS scores decreased from 9.4 to 6.1 after DBS. The average decrease in VAS was 55% for post-traumatic facial pain (2 patients), 45% for poststroke (2 patients), 15% for postherpetic neuralgia (2 patients), and 0% for atypical facial pain (1 patient). Three of the 8 implanted patients (38%) had complications which required removal of hardware. Only 2 of 7 (29%) patients met classical criteria for responders (50% decrease in pain scores). However, among 4 patients who were asked about willingness to undergo DBS again, all expressed that they would repeat the procedure. There is a trend towards improvement in pain scores following DBS for facial pain, most prominently with post-traumatic pain.

Sections du résumé

BACKGROUND
Deep brain stimulation (DBS) has been used for chronic pain for decades, but its use is limited due to a lack of reliable data about its efficacy for specific indications.
OBJECTIVE
To report on 9 patients who underwent DBS for facial pain, with a focus on differences in outcomes between distinct etiologies.
METHODS
We retrospectively reviewed 9 patients with facial pain who were treated with DBS of the ventral posteromedial nucleus of the thalamus and periventricular gray. We report on characteristics including facial pain etiology, complications, changes in pain scores using the visual analog scale (VAS), and willingness to undergo DBS again.
RESULTS
Nine patients underwent DBS for either poststroke, post-traumatic, postherpetic, or atypical facial pain. Eight patients (89%) were permanently implanted. Seven patients had sufficient follow-up (mean 40.3 mo). Of these 7 patients, average VAS scores decreased from 9.4 to 6.1 after DBS. The average decrease in VAS was 55% for post-traumatic facial pain (2 patients), 45% for poststroke (2 patients), 15% for postherpetic neuralgia (2 patients), and 0% for atypical facial pain (1 patient). Three of the 8 implanted patients (38%) had complications which required removal of hardware. Only 2 of 7 (29%) patients met classical criteria for responders (50% decrease in pain scores). However, among 4 patients who were asked about willingness to undergo DBS again, all expressed that they would repeat the procedure.
CONCLUSION
There is a trend towards improvement in pain scores following DBS for facial pain, most prominently with post-traumatic pain.

Identifiants

pubmed: 32542398
pii: 5857687
doi: 10.1093/ons/opaa170
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

510-517

Informations de copyright

Copyright © 2020 by the Congress of Neurological Surgeons.

Auteurs

Alon Kashanian (A)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

Jasmine A T DiCesare (JAT)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

Pratik Rohatgi (P)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

Luigi Albano (L)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.
Department of Neurosurgery, Vita-Salute San Raffaele University and San Raffaele Scientific Institute, Milan, Italy.

Scott E Krahl (SE)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.
VA Greater Los Angeles Healthcare System, Los Angeles, California.

Ausaf Bari (A)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.
VA Greater Los Angeles Healthcare System, Los Angeles, California.

Antonio De Salles (A)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

Nader Pouratian (N)

Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, California.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH